Clinical oncology (Royal College of Radiologists (Great Britain)), cilt.15, sa.3, ss.132-5, 2003 (SCI-Expanded)
Aim: The aim of the current trial was to assess the efficacy and toxicity of 3-weekly intravenous docetaxel and irinotecan in the treatment of patients with metastatic malignant melanoma.